Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lipid nanoparticle-encapsulated EBV mRNA vaccine mRNA-1189

A vaccine consisting of a lipid nanoparticle (LNP) encapsulating four messenger RNAs (mRNAs) encoding the Epstein-Barr Virus (EBV) envelope glycoproteins gp42, gp220, gH and gL, with potential immunizing activity against EBV. Upon intramuscular administration of LNP-encapsulated EBV mRNA vaccine mRNA-1189, the LNP binds to the plasma membrane of cells and releases the mRNAs into the cells. The mRNAs are then translated by ribosomes to produce the EBV envelope glycoproteins. This may activate both humoral and cellular immune responses which may result in protection against EBV infection. EBV, a ubiquitous human herpes virus, is associated with infectious mononucleosis and various malignancies, including nasopharyngeal carcinoma, Hodgkin disease, non-Hodgkin lymphoma, and other lymphomas.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-EBV mRNA vaccine mRNA-1189
LNP-encapsulated EBV mRNA vaccine mRNA-1189
LNP-encapsulated mRNA-based EBV vaccine mRNA-1189
Code name:mRNA 1189
mRNA-1189
mRNA1189
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search